What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Capricor Therapeutics (NASDAQ: CAPR) reports sustained efficacy and safety in 4-year DMD trial of Deramiocel Capricor Therapeutics reports 4-year HOPE-2 data for Deramiocel in Duchenne, showing cardiac stability and slowed muscle decline. Read how it may shape future FDA decisions. byPallavi MadhirajuJune 20, 2025